Akebia Therapeutics (NASDAQ:AKBA) Cut to Market Perform at Leerink Partners

Дата публикации: 10-08-2026 05:24:48

Leerink Partners downgraded shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from an outperform rating to a market perform rating in a research note released on Friday morning, Marketbeat reports. The firm currently has $1.00 price objective on the biopharmaceutical company’s stock. Other equities analysts have also recently issued reports about the company. Weiss Ratings […]

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Oppenheimer Cuts AGI (NYSE:AGBK) Price Target to $9.00	0	10.78	10-08-2026
2	Piper Sandler Cuts Abacus Global Management (NYSE:ABX) Price Target to $12.00	0	10.81	10-08-2026
3	Axcelis Technologies (NASDAQ:ACLS) Cut to “Hold” at Craig Hallum	0	8.86	10-08-2026
4	Truist Financial Cuts Albemarle (NYSE:ALB) Price Target to $225.00	0	11.13	10-08-2026
5	Definium Therapeutics’ (DFTX) “Overweight” Rating Reiterated at Piper Sandler	0	8.75	10-08-2026
6	Guggenheim Cuts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $23.00	0	9.15	10-08-2026
7	Keefe, Bruyette & Woods Cuts Priority Technology (NASDAQ:PRTH) Price Target to $6.50	0	12.25	10-08-2026
8	Akamai Technologies (NASDAQ:AKAM) Price Target Raised to $190.00	0	12.21	10-08-2026
9	Needham & Company LLC Cuts TechTarget (NASDAQ:TTGT) Price Target to $8.00	0	13	10-08-2026
10	Blackrock Tcp Capital (NASDAQ:TCPC) Upgraded at Keefe, Bruyette & Woods	0	7.99	10-08-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.79. Источник: www.americanbankingnews.com.